Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Gynecol Oncol. 2019 Mar;152(3):514–521. doi: 10.1016/j.ygyno.2018.11.027

Table 2.

Visual Analog Scale and Standard Gamble Scores for Screening and Prevention Health States (N=61 women)

Health state Visual analog scale1 Standard Gamble2
Score Score % risk of developing cancer
Median (range) SD Median (range) SD Median (range) SD
Perfect Health (VAS only) 1.00 (.80, 1.00) .05 N/A N/A N/A N/A
Current Health (VAS only) .85 (.40, .99) .11 N/A N/A N/A N/A
Death (VAS only) .00 (.00, 1.00) .11 N/A N/A N/A N/A
Chemoprevention with oral contraceptives .85 (.00, 1.00) .29 .80 (.00, 1.00) .30 20.0 (0.0, 100.0) 29.79
Annual colonoscopy .90 (.10, 1.00) .22 .78 (0.00, 1.00) .24 22.5 (0.0, 100.0) 24.15
Biannual colonoscopy .85 (.00, 1.00) .23 .80 (.10, 1.00) .20 20.0 (0.00, 90.0) 19.62
Annual endometrial biopsy, transvaginal ultrasound, CA 125 .90 (.10, 1.00) .20 .70 (.30, 1.00) .20 30.0 (0.0, 70.0) 19.70
Biannual endometrial biopsy, transvaginal ultrasound, CA 125 .80 (.00, 1.00) .21 .80 (.40, 1.00) .17 20.0 (0.0, 60.0) 17.21
Annual combined screening consisting of colonoscopy and endometrial biopsy, transvaginal ultrasound, CA 125 .98 (.10, 1.00) .16 .75 (.20, 1.00) .23 22.5 (0.0, 80.0) 23.27
Biannual combined screening colonoscopy and endometrial biopsy, transvaginal ultrasound, CA 125 .85 (.00, 1.00) .22 .80 (.30, 1.00) .18 20.0 (0.0, 70.0) 18.27
Prophylactic HYST/BSO (pre-menopausal) .50 (.00, 1.00) .32 .40 (0.00, 1.00) .28 60.0 (0.0, 100.0) 28.34
Prophylactic HYST/BSO (post-menopausal) .85 (.00, 1.00) .26 .60 (0.00, 1.00) .26 40.0 (0.0, 100.0) 26.18

SD=standard deviation

1

Visual analog scale: Health states were ranked from 0 (least preferred) to 100 (most preferred). Preference scores were calculated by dividing the number corresponding to health state rankings by 100 (i.e., 75/100 = .75). Scores closer to 1.0 reflect more favorable health states.

2

Standard gamble: Scores for health states were calculated by subtracting patients’ stated threshold of lifetime disease risk from 100% and dividing that difference by 100 to arrive at a score on a 0.0 to 1.0 scale (0.0 = least favorable; 1.0=most favorable). Percent risk of developing cancer was defined as the threshold of lifetime risk of endometrial and colorectal (0% to 100%) at which patients would consider undertaking the risk management strategy depicted in each health state.